Zevra Therapeutics (ZVRA) asked shareholders in a preliminary proxy statement late Monday to vote down the director nominees proposed by activist investor Daniel J. Mangless and elect the two incumbent members at the next annual shareholders meeting.
One member Mangless nominated is former Zevra chief executive Travis Mickle, who stepped down from the company in January 2023, but continued in an advisory role at Zevra until last October. Mickle's association with the company means he cannot be considered independent.
Mangless also nominated Arthur Regan, who is founder of a proxy solicitation firm he hired to assist with a successful bid to replace several other board members in 2023.
Zevra is asking shareholders to return Wendy Dixon and Tamara Favorito to the board. Dixon has been a board member since 2023 and Favorito began in 2021. The company has not yet set a date for its 2025 annual meeting.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。